Abstract
FLT3 mutations drive acute myeloid leukemia (AML) progression through aberrant signaling, making FLT3 inhibition a key therapeutic strategy. Current inhibitors show efficacy, yet resistance and toxicity remain challenges. Emerging approaches, including selective inhibitors, proteolysis-targeting chimeras, and protein degraders, offer enhanced potency, sustained suppression, and combinatorial potential, representing a precision-based advancement in AML treatment.
| Original language | English |
|---|---|
| Pages (from-to) | 244-247 |
| Number of pages | 4 |
| Journal | Trends in Pharmacological Sciences |
| Volume | 47 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - Mar 2026 |
| Externally published | Yes |
Bibliographical note
Publisher Copyright:© 2026 The Author(s)
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- FLT3 inhibitors
- acute myeloid leukemia
- antibody-drug conjugates
- drug resistance
Fingerprint
Dive into the research topics of 'Evolving paradigms in targeting FLT3 for acute myeloid leukemia therapy'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver